Associations - Tepmetko (tepotinib)

MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	tepotinib Sensitive: A2 - Guideline tepotinib Sensitive : A2	tepotinib Sensitive: A2 - Guideline tepotinib Sensitive : A2
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1
MET exon 14 mutation	Gastric Cancer	MET exon 14 mutation	Gastric Cancer	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1
MET amplification	Lung Cancer	MET amplification	Lung Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET amplification	Gastric Cancer	MET amplification	Gastric Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3
EGFR mutation + MET overexpression	Non Small Cell Lung Cancer	EGFR mutation + MET overexpression	Non Small Cell Lung Cancer	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3
MET overexpression	Hepatocellular Cancer	MET overexpression	Hepatocellular Cancer	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3
MET amplification	Non Small Cell Lung Cancer	MET amplification	Non Small Cell Lung Cancer	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3
EGFR wild-type + MET amplification	Non Small Cell Lung Cancer	EGFR wild-type + MET amplification	Non Small Cell Lung Cancer	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3
MET amplification + EGFR mutation	Non Small Cell Lung Cancer	MET amplification + EGFR mutation	Non Small Cell Lung Cancer	osimertinib + tepotinib Sensitive: C3 – Early Trials osimertinib + tepotinib Sensitive : C3	osimertinib + tepotinib Sensitive: C3 – Early Trials osimertinib + tepotinib Sensitive : C3
EGFR mutation + MET-CEP7 fusion	Non Small Cell Lung Cancer	EGFR mutation + MET-CEP7 fusion	Non Small Cell Lung Cancer	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3	gefitinib + tepotinib Sensitive: C3 – Early Trials gefitinib + tepotinib Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib + capmatinib Sensitive: C3 – Early Trials tepotinib + capmatinib Sensitive : C3	tepotinib + capmatinib Sensitive: C3 – Early Trials tepotinib + capmatinib Sensitive : C3
MET amplification + RB1 wild-type	Non Small Cell Lung Cancer	MET amplification + RB1 wild-type	Non Small Cell Lung Cancer	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3
HLA-DRB1-MET fusion	Non Small Cell Lung Cancer	HLA-DRB1-MET fusion	Non Small Cell Lung Cancer	tepotinib Sensitive: C4 – Case Studies tepotinib Sensitive : C4	tepotinib Sensitive: C4 – Case Studies tepotinib Sensitive : C4
MET exon 14 mutation + MET amplification + PD-L1 overexpression	Lung Adenocarcinoma	MET exon 14 mutation + MET amplification + PD-L1 overexpression	Lung Adenocarcinoma	tepotinib Sensitive: C4 – Case Studies tepotinib Sensitive : C4	tepotinib Sensitive: C4 – Case Studies tepotinib Sensitive : C4
PD-L1 overexpression + MET exon 14 mutation	Non Small Cell Lung Cancer	PD-L1 overexpression + MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: C4 – Case Studies tepotinib Sensitive : C4	tepotinib Sensitive: C4 – Case Studies tepotinib Sensitive : C4
MET overexpression + MUC5B overexpression	Gastric Cancer	MET overexpression + MUC5B overexpression	Gastric Cancer	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D
MET positive	Gastric Cancer	MET positive	Gastric Cancer	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D	tepotinib Sensitive: D – Preclinical tepotinib Sensitive : D

Tepmetko (tepotinib)

Associations
(24)

Associations
(24)

Tepmetko (tepotinib)

Associations(24)

Associations(24)

Associations
(24)

Associations
(24)